Adoptive transfer of Ag-specific T cells to prevent CMV disease after allogeneic stem-cell transplantation

Cytotherapy

Volumn 4, Issue 1, 2002, Pages 3-10

  Van Rhee, F ^a   Barrett, J ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; CMV specific T cells; Management of CMV post allo SCT

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; PEPTIDE; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOTRANSPLANTATION; CELL CLONING; CELL SPECIFICITY; CELLULAR IMMUNITY; COST OF ILLNESS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; INFECTION; LYMPHOCYTE TRANSFER; LYMPHOID CELL LINE; MEDICAL LITERATURE; NEUTROPENIA; NONHUMAN; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

EID: 0036308230     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532402317251473     Document Type: Review

References (62)

1. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: Final report from a longitudinal study
2. Polymerase chain reaction for detection of human cytomegalovirus infection in a blood donor population
3. + cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome
4. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells
5. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
6. Risk factors after human bone marrow transplantation
7. Cytomegalovirus pneumonia after bone marrow transplantation: Risk factors and response to therapy
8. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous immunoglobulin in patients with bone marrow transplant
9. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants
10. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
11. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants [The City of Hope-Stanford-Syntex CMV Study Group]
12. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipient. Results of a placebo-controlled, double blind trial
13. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment: A randomized double-blind study
14. Ganciclovir prophylaxis to prevent cytomegalovirus infection after allogeneic marrow transplant
15. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome
16. Cytomegalovirus isolate resistant to gancoclovir and foscarnet from a marrow transplant patient
17. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
18. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients
19. European Survey of herpes virus resistance to antiviral drugs in bone marrow transplant recipients
20. Factors influencing third party payer cost for allogeneic BMT
21. Human cytomegalovirus-specific T-cytotoxic T cells: Their precursor frequency and stage specificity
22. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation
23. Cytotoxic T cells in cytomegalovirus infection
24. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow transplantation
25. Use of gene modified virus specific T lymphocytes to control Epstein-Barr virus related lymphoproliferation
26. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
27. + virus-specific cytotoxic T lymphocytes
28. Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response
29. Proliferative T cell responses to four human cytomegalovirus (HCMV)-specific proteins in healthy subjects and solid organ transplant recipients
30. Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells
31. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL
32. The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo
33. Development of a candidate HLA-A*0201 restricted peptide-based vaccine against human cytomegalovirus infection
34. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus
35. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
36. Generation of cytomegalovirus-specific cytolytic T cell lines and clones using pp65 transfected dendritic cells
37. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65
38. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant
39. Generating cytotoxic T lymphocytes against cervical cancer with lentivirus-transduced antigen-presenting cells. Third Annual Meeting of the American Society of Gene Therapy
40. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: A novel culture system free of live CMV virions
41. Ligation of CD40 on dendritic cells triggers production of high level of interleukin-12 and enhances T cell stimulatory capacity: T:T help via APC activation
42. + CTL responses in vitro
43. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process
44. Principles of cytomegalovirus antigen presentation in vitro and in vivo
45. The human cytomegalovirus US11 gene product dislocates MHC class 1 heavy chains from the endoplasmic reticulum to the cytosol
46. Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class assembly
47. +-T-cell response to human cytomegalovirus: The 72-kilodalton major immediate-early protein revisited
48. Frequencies of HLA-A2 alleles in five US population groups
49. T cell receptor-MHC class I peptide interactions: Affinity, kinetics, and specificity
50. Phenotypic analysis of antigen-specific T lymphocytes
51. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
52. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
53. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected Rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
54. + T cell with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy
55. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes
56. + CTL
57. Separating GvHD and GvL reactions
58. + T cells usable in immunotherapy
59. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion
60. Flow cytometric determination of intracellular or secreted IFNγ for the quantification of antigen reactive T cells
61. Magnetic selection of cytomegalovirus-specific CTLs for use in antigen-specific donor leukocyte infusion
62. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers